國際醫學(000516.SZ):子公司已收到全部股份轉讓款7.8億元
格隆匯 3 月 22日丨國際醫學(000516.SZ)公佈,公司於2020年11月17日召開第十一屆董事會第十七次會議,並於2020年12月3日召開2020年第三次臨時股東大會,審議通過了《關於出售參股公司北京漢氏聯合生物技術股份有限公司股份的議案》。決定將公司全資子公司西安國際醫學中心有限公司(“醫學中心”)持有的北京漢氏聯合生物技術股份有限公司(“漢氏聯合”)全部3400萬股股份(佔漢氏聯合全部股份的31.36%),以7.8億元的價格出售給濟南銀豐格物長盈醫療科技合夥企業(有限合夥)(“濟南銀豐”)。
近日,醫學中心已收到濟南銀豐支付的第二筆股份轉讓款3.8億元。截止本公吿披露之日,醫學中心已收到全部股份轉讓款合計7.8億元,並協助濟南銀豐完成漢氏聯合股權變更程序,該股份轉讓事項已完成。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.